R&D News | pharmaphorum

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

News

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

News

US puts $25m behind Cellino's cell and tissue printing tech

Cellino Biotech has received funding from the US government to develop a scalable biomanufacturing platform for personalised regenerative medicines derived from patients' own stem cells.

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

ESMO: Incyte's PD-1 treads new ground in anal cancer

ESMO: GSK, iTeos bring some optimism back to TIGIT

ESMO: Enhertu shows its worth in brain metastases

US puts $25m behind Cellino's cell and tissue printing tech

Euro VCs team up to invigorate life sciences ecosystem

How to meet your physicians where they are online

News

Editor's Picks